Drug General Information
Drug ID	D05RVA
Former ID	DIB000432
Drug Name	CFG920
Indication	Metastatic castration-resistant prostate cancer [ICD9: 140-229, 185; ICD10:C61]		Phase 1/2	[532436]
Company	Novartis pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	17 alpha-hydroxylase-C17, 20-lyase	Target Info	Inhibitor	[532436]
BioCyc Pathway	Superpathway of steroid hormone biosynthesis
	Glucocorticoid biosynthesis
	Androgen biosynthesis
KEGG Pathway	Steroid hormone biosynthesis
	Metabolic pathways
	Ovarian steroidogenesis
	Prolactin signaling pathway
PathWhiz Pathway	Androgen and Estrogen Metabolism
	Steroidogenesis
Reactome	Androgen biosynthesis
	Glucocorticoid biosynthesis
	Endogenous sterols
WikiPathways	Metapathway biotransformation
	Steroid Biosynthesis
	Oxidation by Cytochrome P450
	Metabolism of steroid hormones and vitamin D
	Glucocorticoid & Mineralcorticoid Metabolism
	Prostate Cancer
	Phase 1 - Functionalization of compounds
References
Ref 532436	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78.
Ref 532436	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.